According to a recent study, induction therapy with ixekizumab in patients with moderate-to-severe plaque psoriasis may offer faster symptom relief but shows lower long-term drug survival.
According to a recent study, induction therapy with ixekizumab in patients with moderate-to-severe plaque psoriasis may offer faster symptom relief but shows lower long-term drug survival.
HealthMinute.TV 